Hong Kong panel advises single dose of BioNTech COVID shot for teens



By Farah Master

HONG KONG, Sept 16 (Reuters) - A panel of health experts advising the Hong Kong government has recommended children aged 12-17 should get only one dose of BioNTech's 22UAy.DE COVID-19 vaccine after reports of heart inflammation as a side effect.

Professor Lau Yu-lung, who chairs the health committee advising the government on its vaccination programme, told public broadcaster RTHK the side effect was more prevalent than originally thought.

He said experts decided it was better for teenagers to get only one dose to "greatly reduce the chance of heart inflammation". Hong Kong's low COVID-19 risk also means that one dose should offer sufficient protection, he said.

The Asian financial hub has largely controlled the coronavirus, with no locally transmitted cases in many weeks.

Government data shows that 41 cases involving heart inflammation have been reported from people who took the BioNTech vaccine as of end-August, or just 0.0009%.

Among these cases, 16 involved adolescents aged 12-15 or 0.008% of those vaccinated in that age group. Their symptoms resolved after treatment.

Hong Kong has been using two COVID-19 vaccines, namely the Sinovac SVA.O and BioNTech shots. But people aged 12-17 are eligible only for the BioNTech vaccine.

Hong Kong has administered 448,800 doses for this age group and around 65%, or 290,000 adolescents, have had at least one vaccine dose.

Regulators in the United States, the European Union and the World Health Organization have said that mRNA vaccines from BioNTech/Pfizer PFE.N and by Moderna MRNA.O are associated with rare cases of myocarditis or pericarditis, but that the benefits of the shots outweigh the risks.

Myocarditis is an inflammation of the heart muscle that can limit the organ's ability to pump blood and can cause changes in heartbeat rhythms. Pericarditis is an inflammation of the lining around the heart.

Pfizer has said it  recognised there could be rare reports of myocarditis after vaccinations but that such side effects were extremely rare.

BioNTech and its Chinese sales agent, Shanghai Fosun Pharmaceutical Group 600196.SS , did not immediately reply to requests for comment.

The risk of myocarditis was 18.5 per million doses given among people aged 18 to 24 after their second Pfizer dose, and 20.2 per million for that age group for recipients of a Moderna second dose. The risk decreases with age, according to data from the U.S. Centers for Disease Control and Prevention.

The British government on Monday said Link England would begin vaccinating those aged 12-15 next week, using the Pfizer/BioNTech shot, but that second doses would not be offered to the age group until at least spring, as its top medical advisers wait for more data from around the world.

Norway said Link earlier this month it would also begin to offer a single dose of the Pfizer/BioNTech vaccine to those aged 12-15 and a decision on second doses would come later.

Around 65% of Hong Kong's residents have had their first vaccine dose, but the take-up by older people remains low due to concerns about side effects.

Hong Kong has recorded around 12,100 COVID-19 cases and 213 deaths.
Reporting by Farah Master; Additional reporting by Gwladys Fouche in Oslo; Editing by Miyoung Kim, Lincoln Feast and Tom Hogue

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Usamos cookies para lhe dar a melhor experiência no nosso website. Ler mais ou alterar as configurações de cookies.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.